ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
about
Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation.Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.[Molecular pathology of the lungs. New perspectives by next generation sequencing].
P2860
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
@en
type
label
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
@en
prefLabel
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
@en
P2093
P2860
P1433
P1476
ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
@en
P2093
Itziar Eraña-Tomás
Jose Rafael Carrión-Galindo
Luis Cabezón-Gutiérrez
María Castro-Otero
Parham Khosravi-Shahi
Victor Manuel Diaz-Muñoz-de-la-Espada
P2860
P2888
P304
P356
10.1007/S00408-012-9391-Y
P577
2012-05-15T00:00:00Z
P6179
1015204055